PFE Jan 2025 40.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:16AM EDT. Market open.
| Previous close | 0.1300 |
| Open | 0.1200 |
| Bid | 0.1000 |
| Ask | 0.1200 |
| Strike | 40.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1100 - 0.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | 47.47k |
ZacksModerna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
ZacksPharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
Business WireELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
NEW YORK, June 14, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
© 2024 Yahoo. All rights reserved.